D. F. Smith, D. O. Toft (1993). Steroid receptors and their associated proteins. Mol. Endocrinol. 4 :7.
Y. Tabata, H. Osada (2003). Estrogen and progesterone receptors as molecular targets for anti-
cancer drug. Drug Deliv. Syst. 18: 336–342.
M. R. Walters (1985). Steroid hormone receptors and the nucleus. Endocrinol. Rev. 6: 512–543.
Peptide Hormones
M. R. Bell, F. H. Batzold, R. C. Winekker (1986). Chemical control of fertility. Annu.Rep. Med.
Chem. 21 : 169–177.
P. M. Conn (1984). Molecular mechanism of gonadotropin releasing hormone action. In:
G. Litwack (Ed.). Biochemical Action of Hormones, vol. 11. New York: Academic Press,
pp. 67–92.
F. V. DeFeudis, J.-P. Moreau (1986). Studies on somatostatin analogs might lead to new therapies
for certain types of cancer. Trends Pharmacol. Sci. 7: 384–386.
A. S. Dutta, B. J. A. Furr (1985). Luteinizing hormone releasing hormone (LHRH) analogs.
Annu. Rep. Med. Chem. 20: 203–214.
A. M. Felix, E. P. Heimer, T. F. Mowles (1985). Growth hormone releasing factors. Annu. Rep.
Med. Chem. 20 : 195–192.
D. M. Gash, G. J. Thomas (1985). What is the importance of vasopressin in memory processes?
In: D. Bousfield (Ed.). Neurotransmitters in Action. Amsterdam: Elsevier, pp. 305–308.
R. Guillermo, P. Brazeau, P. Böhlen, F. Esch, N. Ling, W. B. Wehrenberg, B. Bloch, C. Mougin,
F. Zeytin, A. Baird (1984). Somatocrinin, the growth hormone releasing factor. In:
R. O. Greep (Ed.). Recent Progress in Hormone Research, vol. 40. New York: Academic
Press, pp. 233–299.
W. K. Hagmann (2002). Therapeutic applications of non-peptidic δ-opioid agonists. Ann. Rep.
Med. Chem. 37: 159.
V. J. Hruby (1985). Design of peptide hormone and neurotransmitter analogs. Trends Pharmacol.
Sci. 6 : 259–262.
R. M. Jones, P. D. Boatman, G. Semple, Y.-J. Shin, S. Y. Tamura (2003). Clinically validated
peptides as templates for de novo peptidomimetic drug design at G-protein-coupled recep-
tors.Curr. Opin. Pharmacol. 3: 530–543.
D. Larhammar (1996). Structural diversity of receptors for neuropeptide Y, peptide YY and
pancreatic polypeptide. Regul. Pept. 65: 165.
D. R. Lynch, S. H. Snyder (1986). Neuropeptides: multiple molecular forms, metabolic pathways,
and receptors. Annu. Rev. Biochem. 55: 773–799.
J. van Nispen, R. Pinder (1986). Formation and degradation of neuropeptides. Annu. Rep. Med.
Chem. 21: 51–62.
D. Regoli, A. Boudon, and J.-L. Fauchere (1994). Pharmacol. Rev. 46: 551.
A. V. Schally, D. H. Coy, C. A. Meyers (1978). Hypothalamic regulatory hormones. Annu. Rev.
Biochem. 47: 89–118.
E. J. Trybulski (2001). Vasopressin receptor modulators: from non-peptide antagonists to
agonists.Ann. Rep. Med. Chem. 36 : 159.
P. Vermeij, D. Blok (1996). New peptide and protein drugs. Pharm. World Sci. 18: 87–93.
Thyroid Hormones
E. N. Cheung (1995). Thyroid hormone action: determination of hormone–receptor interaction
using structural analogs and molecular modeling. Trends Pharmacol. Sci. 6:31–34.
D. S. Cooper (1984). Antithyroid drugs. N. Engl. J. Med. 311: 1353–1357.
HORMONES AND THEIR RECEPTORS 383